Author(s):
Dhinakaran S, Tamilanban T, Chitra V
Email(s):
dhina1676@gmail.com , veera.srm@gmail.com , velchitram74@gmail.com
DOI:
10.5958/0974-360X.2019.00521.3 
Address:
Dhinakaran S1, Tamilanban T2*, Chitra V3
1PG Scholar, Department of Pharmacology, SRM College of Pharmacy, SRM Institution of Science and Technology, Kattangulathur – 603203, Tamil Nadu, India.
2Associate Professor, Department of Pharmacology, SRM College of Pharmacy, SRM Institution of Science and Technology, Kattangulathur – 603203, Tamil Nadu, India.
3Professor and Head of the Department, Department of Pharmacology, SRM College of Pharmacy, SRM Institution of Science and Technology, Kattangulathur – 603203, Tamil Nadu, India.
*Corresponding Author
Published In:
Volume - 12,
Issue - 6,
Year - 2019
ABSTRACT:
AD is predominant of causing mortality across the world. Various type of hallmarks has been exploring in this disease, like aggregates of ß-amyloid, hyperphosphorylated tau proteins, dyshomeostasis of biometals, oxidative stress, reduction in Ach, etc. There is no test to diagnose AD and it not simple. The majority of putative disease-modifying treatments in development for Alzheimer's disease directed against the amyloid-ß (A ß) peptide. AD allowed for the development of the first generation of therapies that are somewhat specific for this disorder. Acetylcholine esterase, ß-secretase, tau protein and NMDA are the essential targets involves in the treatment of Alzheimer’s disease. AChE inhibitors and NMDA blockade have proven that higher efficacy levels in AD and many authors considering that as "symptomatic" treatments.
Cite this article:
Dhinakaran S, Tamilanban T, Chitra V. Targets for Alzheimer’s Disease. Research J. Pharm. and Tech. 2019; 12(6):3073-3077. doi: 10.5958/0974-360X.2019.00521.3
Cite(Electronic):
Dhinakaran S, Tamilanban T, Chitra V. Targets for Alzheimer’s Disease. Research J. Pharm. and Tech. 2019; 12(6):3073-3077. doi: 10.5958/0974-360X.2019.00521.3 Available on: https://rjptonline.org/AbstractView.aspx?PID=2019-12-6-84